2023
Acquired Disorders of Hypomagnesemia
Rosner M, Ha N, Palmer B, Perazella M. Acquired Disorders of Hypomagnesemia. Mayo Clinic Proceedings 2023, 98: 581-596. PMID: 36872194, DOI: 10.1016/j.mayocp.2022.12.002.Peer-Reviewed Original ResearchConceptsReduced glomerular filtration rateBody storesBody magnesium storesGlomerular filtration rateSerum magnesium levelsTotal body storesDevelopment of symptomsIntravenous replacementOrgan dysfunctionMagnesium disordersRenal lossMagnesium replacementFiltration rateSevere casesMagnesium storesHypomagnesemiaClinical experienceClinical practiceMagnesium levelsAcquired disordersAmphotericin BMagnesium handlingOptimal managementMedicationsLaboratory assessment
2020
Urine interleukin-9 and tumor necrosis factor-α for prognosis of human acute interstitial nephritis
Moledina DG, Wilson FP, Kukova L, Obeid W, Luciano R, Kuperman M, Moeckel GW, Kashgarian M, Perazella MA, Cantley LG, Parikh CR. Urine interleukin-9 and tumor necrosis factor-α for prognosis of human acute interstitial nephritis. Nephrology Dialysis Transplantation 2020, 36: 1851-1858. PMID: 33125471, PMCID: PMC8476079, DOI: 10.1093/ndt/gfaa169.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisTumor necrosis factorCorticosteroid useIL-9Interstitial nephritisNecrosis factorAcute kidney injuryIL-9 levelsGlomerular filtration rateSubset of patientsCohort of participantsImmunosuppressive therapyTubulointerstitial infiltratesKidney injuryMedian eGFRKidney functionUrine biomarkersInterstitial fibrosisFiltration rateHistological featuresClinical trialsInterleukin-9PatientsEGFRComplete dataNSAIDs in CKD: Are They Safe?
Baker M, Perazella MA. NSAIDs in CKD: Are They Safe? American Journal Of Kidney Diseases 2020, 76: 546-557. PMID: 32479922, DOI: 10.1053/j.ajkd.2020.03.023.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonsteroidal anti-inflammatory drugsChronic kidney diseaseGlomerular filtration rateFiltration rateRisk factorsHigh pain burdenAcute kidney injuryManagement of painAnti-inflammatory drugsCKD populationNSAID useKidney injuryPain burdenPain controlHeart failureComorbid conditionsElectrolyte derangementsKidney diseaseSafety dataDrug effectsPatientsIndividualized basisDrug metabolismProgressive lossCautious useHow to determine kidney function in cancer patients?
Sprangers B, Abudayyeh A, Latcha S, Perazella MA, Jhaveri KD. How to determine kidney function in cancer patients? European Journal Of Cancer 2020, 132: 141-149. PMID: 32361629, DOI: 10.1016/j.ejca.2020.03.026.Peer-Reviewed Original ResearchConceptsGlomerular filtration rateKidney functionCancer patientsDifferent glomerular filtration ratesAppropriate dose adjustmentCKD-EPI formulaSerum creatinine concentrationNarrow therapeutic indexDose adjustmentFiltration rateClinical trialsCreatinine concentrationTherapeutic indexAnti-cancer drugsPatientsToxic drugsDrugsBody surfaceTrialsNomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference
Levey AS, Eckardt KU, Dorman NM, Christiansen SL, Hoorn EJ, Ingelfinger JR, Inker LA, Levin A, Mehrotra R, Palevsky PM, Perazella MA, Tong A, Allison SJ, Bockenhauer D, Briggs JP, Bromberg JS, Davenport A, Feldman HI, Fouque D, Gansevoort RT, Gill JS, Greene EL, Hemmelgarn BR, Kretzler M, Lambie M, Lane PH, Laycock J, Leventhal SE, Mittelman M, Morrissey P, Ostermann M, Rees L, Ronco P, Schaefer F, St Clair Russell J, Vinck C, Walsh SB, Weiner DE, Cheung M, Jadoul M, Winkelmayer WC. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney International 2020, 97: 1117-1129. PMID: 32409237, DOI: 10.1016/j.kint.2020.02.010.Peer-Reviewed Original ResearchConceptsAcute kidney injuryChronic kidney diseaseGlomerular filtration rateKidney diseaseKidney functionKDIGO definitionConsensus conferenceSeverity of CKDEnd-stage kidney diseaseAcute kidney diseaseAbsence of symptomsGlobal Outcomes (KDIGO) Consensus ConferenceKDIGO guidelinesKidney injuryKidney failureKidney measuresFiltration rateWorldwide burdenGlobal outcomeKidney structureDiseaseHealth communitySeverityFollowing recommendationsMore effective communicationSGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern?
Baker ML, Perazella MA. SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern? Journal Of Nephrology 2020, 33: 985-994. PMID: 32067179, DOI: 10.1007/s40620-020-00712-5.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType 2 diabetes mellitusAcute kidney injuryChronic kidney diseaseDiabetes mellitusKidney diseaseKidney injuryAlbuminuric chronic kidney diseaseEnd-stage kidney diseaseInhibitor drugsSGLT2 inhibitor therapySignificant cardiovascular benefitsHeart failure hospitalizationGlomerular filtration rateAtherosclerotic cardiovascular diseaseLarge clinical trialsFDA adverse eventsBeneficial cardiovascularKidney benefitsSGLT2 transporterCardiovascular deathFailure hospitalizationAdverse eventsCardiovascular benefitsKidney protectionBlood pressureUse of Intravenous Iodinated Contrast Media in Patients With Kidney Disease Consensus Statements from the American College of Radiology and the National Kidney Foundation
Davenport MS, Perazella MA, Yee J, Dillman JR, Fine D, McDonald RJ, Rodby RA, Wang CL, Weinreb JC. Use of Intravenous Iodinated Contrast Media in Patients With Kidney Disease Consensus Statements from the American College of Radiology and the National Kidney Foundation. Kidney Medicine 2020, 2: 85-93. PMID: 33015613, PMCID: PMC7525144, DOI: 10.1016/j.xkme.2020.01.001.Peer-Reviewed Original ResearchAcute kidney injuryGlomerular filtration rateContrast mediumFiltration rateContrast-associated acute kidney injuryContrast-induced acute kidney injuryIntravenous normal salineReduced kidney functionSevere kidney diseaseNational Kidney FoundationIodinated Contrast MediaHigh-risk circumstancesCI-AKIKidney injuryMaintenance dialysisKidney functionKidney diseaseOrdering clinicianNormal salineConsensus statementKidney FoundationTreatment responseAmerican CollegePatientsControl groupUse of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation
Davenport MS, Perazella MA, Yee J, Dillman JR, Fine D, McDonald RJ, Rodby RA, Wang CL, Weinreb JC. Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Radiology 2020, 294: 192094. PMID: 31961246, DOI: 10.1148/radiol.2019192094.Peer-Reviewed Original ResearchConceptsAcute kidney injuryGlomerular filtration rateContrast mediumKidney diseaseFiltration rateContrast-associated acute kidney injuryContrast-induced acute kidney injuryIntravenous normal salineReduced kidney functionSevere kidney diseaseNational Kidney FoundationIodinated Contrast MediaHigh-risk circumstancesSimultaneous joint publicationCI-AKIKidney injuryMaintenance dialysisKidney functionOrdering clinicianNormal salineConsensus statementKidney FoundationTreatment responseAmerican CollegePatients
2000
Trimethoprim-Induced Hyperkalaemia
Perazella M. Trimethoprim-Induced Hyperkalaemia. Drug Safety 2000, 22: 227-236. PMID: 10738846, DOI: 10.2165/00002018-200022030-00006.Peer-Reviewed Original ResearchConceptsRenal potassium excretionPotassium excretionHigh urinary flow ratesPotassium homeostasisManagement of hyperkalaemiaGlomerular filtration ratePotassium-sparing diuretic amilorideUrinary flow rateRecognition of patientsDistal nephron cellsTrimethoprim therapyRenal impairmentCommon complicationLoop diureticsEpithelial sodium channelIntravenous fluidsVolume repletionAdverse reactionsFiltration rateRisk factorsStandard dosageAntikaliuretic effectHyperkalaemiaIsotonic fluidsDistal nephron